ID   GBRG2_HUMAN             Reviewed;         475 AA.
AC   P18507; F5HB82; Q6GRL6; Q6PCC3; Q9UDB3; Q9UN15;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2023, sequence version 3.
DT   28-JUN-2023, entry version 229.
DE   RecName: Full=Gamma-aminobutyric acid receptor subunit gamma-2;
DE   AltName: Full=GABA(A) receptor subunit gamma-2;
DE   Flags: Precursor;
GN   Name=GABRG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION,
RP   SUBUNIT, AND ACTIVITY REGULATION.
RC   TISSUE=Brain;
RX   PubMed=2538761; DOI=10.1038/338582a0;
RA   Pritchett D.B., Sontheimer H., Shivers B.D., Ymer S., Kettenmann H.,
RA   Schofield P.R., Seeburg P.H.;
RT   "Importance of a novel GABAA receptor subunit for benzodiazepine
RT   pharmacology.";
RL   Nature 338:582-585(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11328646; DOI=10.3109/10425170009033988;
RA   Jiang S., Yu J., Wang J., Tan Z., Xue H., Feng G., He L., Yang H.;
RT   "Complete genomic sequence of 195 Kb of human DNA containing the gene
RT   GABRG2.";
RL   DNA Seq. 11:373-382(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ARG-357.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 357-451 (ISOFORM 2).
RC   TISSUE=Brain cortex;
RX   PubMed=8382267; DOI=10.1111/j.1471-4159.1993.tb03243.x;
RA   Khan Z.U., Fernando L.P., Escriba P., Busquets X., Mallet J.,
RA   Miralles C.P., Filla M., De Blas A.L.;
RT   "Antibodies to the human gamma 2 subunit of the gamma-aminobutyric
RT   acidA/benzodiazepine receptor.";
RL   J. Neurochem. 60:961-971(1993).
RN   [6]
RP   INTERACTION WITH GABARAP.
RX   PubMed=9892355; DOI=10.1038/16264;
RA   Wang H., Bedford F.K., Brandon N.J., Moss S.J., Olsen R.W.;
RT   "GABA(A)-receptor-associated protein links GABA(A) receptors and the
RT   cytoskeleton.";
RL   Nature 397:69-72(1999).
RN   [7]
RP   FUNCTION.
RX   PubMed=23909897; DOI=10.1111/ejn.12331;
RA   Fuchs C., Abitbol K., Burden J.J., Mercer A., Brown L., Iball J.,
RA   Anne Stephenson F., Thomson A.M., Jovanovic J.N.;
RT   "GABA(A) receptors can initiate the formation of functional inhibitory
RT   GABAergic synapses.";
RL   Eur. J. Neurosci. 38:3146-3158(2013).
RN   [8]
RP   FUNCTION.
RX   PubMed=25489750; DOI=10.3791/52115;
RA   Brown L.E., Fuchs C., Nicholson M.W., Stephenson F.A., Thomson A.M.,
RA   Jovanovic J.N.;
RT   "Inhibitory synapse formation in a co-culture model incorporating GABAergic
RT   medium spiny neurons and HEK293 cells stably expressing GABAA receptors.";
RL   J. Vis. Exp. 2014:E52115-E52115(2014).
RN   [9]
RP   VARIANTS DEE74 THR-106; THR-107; SER-282; GLN-323; TRP-323 AND LEU-343,
RP   CHARACTERIZATION OF VARIANTS DEE74 THR-106; THR-107; SER-282; GLN-323;
RP   TRP-323 AND LEU-343, SUBCELLULAR LOCATION, FUNCTION, AND ACTIVITY
RP   REGULATION.
RX   PubMed=27864268; DOI=10.1093/brain/aww272;
RA   Shen D., Hernandez C.C., Shen W., Hu N., Poduri A., Shiedley B.,
RA   Rotenberg A., Datta A.N., Leiz S., Patzer S., Boor R., Ramsey K.,
RA   Goldberg E., Helbig I., Ortiz-Gonzalez X.R., Lemke J.R., Marsh E.D.,
RA   Macdonald R.L.;
RT   "De novo GABRG2 mutations associated with epileptic encephalopathies.";
RL   Brain 140:49-67(2017).
RN   [10] {ECO:0007744|PDB:6D6T, ECO:0007744|PDB:6D6U}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.80 ANGSTROMS) OF 8-326 IN COMPLEX WITH
RP   GABA AND FLUMAZENIL, FUNCTION, ACTIVITY REGULATION, AND SUBUNIT.
RX   PubMed=29950725; DOI=10.1038/s41586-018-0255-3;
RA   Zhu S., Noviello C.M., Teng J., Walsh R.M. Jr., Kim J.J., Hibbs R.E.;
RT   "Structure of a human synaptic GABAA receptor.";
RL   Nature 559:67-72(2018).
RN   [11]
RP   VARIANT GEFSP3 MET-328.
RX   PubMed=11326274; DOI=10.1038/ng0501-46;
RA   Baulac S., Huberfeld G., Gourfinkel-An I., Mitropoulou G., Beranger A.,
RA   Prud'homme J.-F., Baulac M., Brice A., Bruzzone R., LeGuern E.;
RT   "First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a
RT   mutation in the gamma2-subunit gene.";
RL   Nat. Genet. 28:46-48(2001).
RN   [12]
RP   VARIANT ECA2/FEB8 GLN-82.
RX   PubMed=11326275; DOI=10.1038/ng0501-49;
RA   Wallace R.H., Marini C., Petrou S., Harkin L.A., Bowser D.N., Panchal R.G.,
RA   Williams D.A., Sutherland G.R., Mulley J.C., Scheffer I.E., Berkovic S.F.;
RT   "Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and
RT   febrile seizures.";
RL   Nat. Genet. 28:49-52(2001).
RN   [13]
RP   VARIANT FEB8 GLY-177.
RX   PubMed=16924025; DOI=10.1212/01.wnl.0000230145.73496.a2;
RA   Audenaert D., Schwartz E., Claeys K.G., Claes L., Deprez L., Suls A.,
RA   Van Dyck T., Lagae L., Van Broeckhoven C., Macdonald R.L., De Jonghe P.;
RT   "A novel GABRG2 mutation associated with febrile seizures.";
RL   Neurology 67:687-690(2006).
RN   [14]
RP   VARIANT SER-79.
RX   PubMed=20485450; DOI=10.1038/jhg.2010.47;
RA   Shi X., Huang M.C., Ishii A., Yoshida S., Okada M., Morita K., Nagafuji H.,
RA   Yasumoto S., Kaneko S., Kojima T., Hirose S.;
RT   "Mutational analysis of GABRG2 in a Japanese cohort with childhood
RT   epilepsies.";
RL   J. Hum. Genet. 55:375-378(2010).
RN   [15]
RP   VARIANT SER-83, AND CHARACTERIZATION OF VARIANT SER-83.
RX   PubMed=21714819; DOI=10.1111/j.1460-9568.2011.07767.x;
RA   Lachance-Touchette P., Brown P., Meloche C., Kinirons P., Lapointe L.,
RA   Lacasse H., Lortie A., Carmant L., Bedford F., Bowie D., Cossette P.;
RT   "Novel alpha1 and gamma2 GABAA receptor subunit mutations in families with
RT   idiopathic generalized epilepsy.";
RL   Eur. J. Neurosci. 34:237-249(2011).
RN   [16]
RP   VARIANT GEFSP3 GLN-323.
RX   PubMed=23708187; DOI=10.1038/ng.2646;
RA   Carvill G.L., Heavin S.B., Yendle S.C., McMahon J.M., O'Roak B.J., Cook J.,
RA   Khan A., Dorschner M.O., Weaver M., Calvert S., Malone S., Wallace G.,
RA   Stanley T., Bye A.M., Bleasel A., Howell K.B., Kivity S., Mackay M.T.,
RA   Rodriguez-Casero V., Webster R., Korczyn A., Afawi Z., Zelnick N.,
RA   Lerman-Sagie T., Lev D., Moeller R.S., Gill D., Andrade D.M., Freeman J.L.,
RA   Sadleir L.G., Shendure J., Berkovic S.F., Scheffer I.E., Mefford H.C.;
RT   "Targeted resequencing in epileptic encephalopathies identifies de novo
RT   mutations in CHD2 and SYNGAP1.";
RL   Nat. Genet. 45:825-830(2013).
RN   [17]
RP   VARIANT CYS-274.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D., Bigoni S.,
RA   Barba C., Mari F., Montomoli M., Pisano T., Rosati A., Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
CC   -!- FUNCTION: Ligand-gated chloride channel which is a component of the
CC       heteropentameric receptor for GABA, the major inhibitory
CC       neurotransmitter in the brain (PubMed:2538761, PubMed:29950725). Plays
CC       an important role in the formation of functional inhibitory GABAergic
CC       synapses in addition to mediating synaptic inhibition as a GABA-gated
CC       ion channel (PubMed:23909897, PubMed:25489750, PubMed:27864268). The
CC       gamma2 subunit is necessary but not sufficient for a rapid formation of
CC       active synaptic contacts and the synaptogenic effect of this subunit is
CC       influenced by the type of alpha and beta subunits present in the
CC       receptor pentamer (By similarity). The alpha1/beta2/gamma2 receptor and
CC       the alpha1/beta3/gamma2 receptor exhibit synaptogenic activity
CC       (PubMed:23909897, PubMed:25489750). The alpha2/beta2/gamma2 receptor
CC       exhibits synatogenic activity whereas the alpha2/beta3/gamma2 receptor
CC       shows very little or no synaptogenic activity (By similarity).
CC       Functions also as histamine receptor and mediates cellular responses to
CC       histamine (By similarity). {ECO:0000250|UniProtKB:P22723,
CC       ECO:0000269|PubMed:23909897, ECO:0000269|PubMed:2538761,
CC       ECO:0000269|PubMed:25489750, ECO:0000269|PubMed:27864268,
CC       ECO:0000269|PubMed:29950725}.
CC   -!- ACTIVITY REGULATION: Allosterically activated by benzodiazepines
CC       (PubMed:2538761, PubMed:29950725). Activated by pentobarbitol (By
CC       similarity). Inhibited by the antagonist bicuculline (PubMed:29950725).
CC       Inhibited by zinc ions (PubMed:27864268).
CC       {ECO:0000250|UniProtKB:P18508, ECO:0000269|PubMed:2538761,
CC       ECO:0000269|PubMed:27864268, ECO:0000269|PubMed:29950725}.
CC   -!- SUBUNIT: Heteropentamer, formed by a combination of alpha, beta, gamma,
CC       delta and rho chains (PubMed:2538761, PubMed:29950725). Interacts with
CC       GABARAP (PubMed:9892355). Interacts with KIF21B (By similarity).
CC       Identified in a complex of 720 kDa composed of LHFPL4, NLGN2, GABRA1,
CC       GABRB2, GABRG2 and GABRB3 (By similarity). Interacts with LHFPL4 (By
CC       similarity). Interacts with SHISA7; interaction leads to the regulation
CC       of GABA(A) receptor trafficking, channel deactivation kinetics and
CC       pharmacology (By similarity). {ECO:0000250|UniProtKB:P18508,
CC       ECO:0000250|UniProtKB:P22723, ECO:0000269|PubMed:2538761,
CC       ECO:0000269|PubMed:29950725, ECO:0000269|PubMed:9892355}.
CC   -!- INTERACTION:
CC       P18507; P51513: NOVA1; NbExp=2; IntAct=EBI-9008430, EBI-726123;
CC       P18507-2; O95166: GABARAP; NbExp=3; IntAct=EBI-15096952, EBI-712001;
CC   -!- SUBCELLULAR LOCATION: Postsynaptic cell membrane
CC       {ECO:0000269|PubMed:2538761}; Multi-pass membrane protein
CC       {ECO:0000255}. Cell membrane {ECO:0000269|PubMed:2538761,
CC       ECO:0000269|PubMed:27864268}; Multi-pass membrane protein
CC       {ECO:0000255}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P22723}. Cytoplasmic vesicle membrane
CC       {ECO:0000250|UniProtKB:P18508}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P18507-2; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P18507-1; Sequence=VSP_061923;
CC       Name=3;
CC         IsoId=P18507-3; Sequence=VSP_061922;
CC   -!- DOMAIN: The extracellular domain contributes to synaptic contact
CC       formation. {ECO:0000250|UniProtKB:P22723}.
CC   -!- PTM: Glycosylated. {ECO:0000250|UniProtKB:P22723}.
CC   -!- PTM: Palmitoylated by ZDHHC3/GODZ; required for the accumulation of
CC       GABA(A) receptors at the postsynaptic membrane of inhibitory GABAergic
CC       synapses. {ECO:0000250|UniProtKB:P22723}.
CC   -!- DISEASE: Developmental and epileptic encephalopathy 74 (DEE74)
CC       [MIM:618396]: A form of epileptic encephalopathy, a heterogeneous group
CC       of severe early-onset epilepsies characterized by refractory seizures,
CC       neurodevelopmental impairment, and poor prognosis. Development is
CC       normal prior to seizure onset, after which cognitive and motor delays
CC       become apparent. DEE74 is an autosomal dominant form with onset in the
CC       first year of life. {ECO:0000269|PubMed:27864268}. Note=The gene
CC       represented in this entry is involved in disease pathogenesis.
CC   -!- DISEASE: Epilepsy, childhood absence 2 (ECA2) [MIM:607681]: A subtype
CC       of idiopathic generalized epilepsy characterized by an onset at age 6-7
CC       years, frequent absence seizures (several per day) and bilateral,
CC       synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures
CC       often develop in adolescence. Some individuals manifest febrile
CC       seizures. Absence seizures may either remit or persist into adulthood.
CC       {ECO:0000269|PubMed:11326275}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Febrile seizures, familial, 8 (FEB8) [MIM:607681]: Seizures
CC       associated with febrile episodes in childhood without any evidence of
CC       intracranial infection or defined pathologic or traumatic cause. It is
CC       a common condition, affecting 2-5% of children aged 3 months to 5
CC       years. The majority are simple febrile seizures (generally defined as
CC       generalized onset, single seizures with a duration of less than 30
CC       minutes). Complex febrile seizures are characterized by focal onset,
CC       duration greater than 30 minutes, and/or more than one seizure in a 24
CC       hour period. The likelihood of developing epilepsy following simple
CC       febrile seizures is low. Complex febrile seizures are associated with a
CC       moderately increased incidence of epilepsy.
CC       {ECO:0000269|PubMed:16924025}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Generalized epilepsy with febrile seizures plus 3 (GEFSP3)
CC       [MIM:607681]: A rare autosomal dominant, familial condition with
CC       incomplete penetrance and large intrafamilial variability. Patients
CC       display febrile seizures persisting sometimes beyond the age of 6 years
CC       and/or a variety of afebrile seizure types. This disease combines
CC       febrile seizures, generalized seizures often precipitated by fever at
CC       age 6 years or more, and partial seizures, with a variable degree of
CC       severity. {ECO:0000269|PubMed:11326274, ECO:0000269|PubMed:23708187}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: This subunit carries the benzodiazepine binding site.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9) family.
CC       Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRG2 sub-
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Forbidden fruit - Issue 56
CC       of March 2005;
CC       URL="https://web.expasy.org/spotlight/back_issues/056";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X15376; CAA33437.1; -; mRNA.
DR   EMBL; AF165124; AAD50273.1; -; Genomic_DNA.
DR   EMBL; AC008611; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091926; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091984; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC059389; AAH59389.1; -; mRNA.
DR   EMBL; BC069348; AAH69348.1; -; mRNA.
DR   EMBL; BC074795; AAH74795.1; -; mRNA.
DR   CCDS; CCDS4358.1; -. [P18507-1]
DR   CCDS; CCDS4359.1; -. [P18507-2]
DR   CCDS; CCDS47333.1; -. [P18507-3]
DR   PIR; S03905; S03905.
DR   RefSeq; NP_000807.2; NM_000816.3. [P18507-1]
DR   RefSeq; NP_944493.2; NM_198903.2. [P18507-3]
DR   RefSeq; NP_944494.1; NM_198904.2. [P18507-2]
DR   PDB; 6D6T; EM; 3.80 A; E=8-326.
DR   PDB; 6D6U; EM; 3.80 A; E=40-361, E=447-475.
DR   PDB; 6HUJ; EM; 3.04 A; C=66-363, C=445-475.
DR   PDB; 6I53; EM; 3.20 A; C=66-362, C=445-475.
DR   PDB; 6X3S; EM; 3.12 A; E=8-361, E=448-475.
DR   PDB; 6X3T; EM; 2.55 A; E=8-361, E=448-475.
DR   PDB; 6X3U; EM; 3.49 A; E=8-361, E=448-475.
DR   PDB; 6X3V; EM; 3.50 A; E=8-361, E=448-475.
DR   PDB; 6X3W; EM; 3.30 A; E=8-361, E=448-475.
DR   PDB; 6X3X; EM; 2.92 A; E=8-361, E=448-475.
DR   PDB; 6X3Z; EM; 3.23 A; E=8-361, E=448-475.
DR   PDB; 6X40; EM; 2.86 A; E=8-361, E=448-475.
DR   PDB; 7QNB; EM; 3.10 A; A/C=51-467.
DR   PDB; 7QNE; EM; 2.70 A; C=1-467.
DR   PDB; 7T0W; EM; 3.00 A; E=40-361, E=448-475.
DR   PDB; 7T0Z; EM; 3.00 A; E=40-361, E=448-475.
DR   PDB; 8DD2; EM; 2.90 A; E=40-361.
DR   PDB; 8DD3; EM; 2.90 A; E=40-361.
DR   PDBsum; 6D6T; -.
DR   PDBsum; 6D6U; -.
DR   PDBsum; 6HUJ; -.
DR   PDBsum; 6I53; -.
DR   PDBsum; 6X3S; -.
DR   PDBsum; 6X3T; -.
DR   PDBsum; 6X3U; -.
DR   PDBsum; 6X3V; -.
DR   PDBsum; 6X3W; -.
DR   PDBsum; 6X3X; -.
DR   PDBsum; 6X3Z; -.
DR   PDBsum; 6X40; -.
DR   PDBsum; 7QNB; -.
DR   PDBsum; 7QNE; -.
DR   PDBsum; 7T0W; -.
DR   PDBsum; 7T0Z; -.
DR   PDBsum; 8DD2; -.
DR   PDBsum; 8DD3; -.
DR   AlphaFoldDB; P18507; -.
DR   SMR; P18507; -.
DR   BioGRID; 108840; 19.
DR   ComplexPortal; CPX-2159; GABA-A receptor, alpha-1/beta-2/gamma-2.
DR   ComplexPortal; CPX-2164; GABA-A receptor, alpha-6/beta-3/gamma-2.
DR   ComplexPortal; CPX-2166; GABA-A receptor, alpha-3/beta-3/gamma-2.
DR   ComplexPortal; CPX-2167; GABA-A receptor, alpha-1/beta-3/gamma-2.
DR   ComplexPortal; CPX-2168; GABA-A receptor, alpha-5/beta-3/gamma-2.
DR   ComplexPortal; CPX-2174; GABA-A receptor, alpha-2/beta-3/gamma-2.
DR   CORUM; P18507; -.
DR   IntAct; P18507; 15.
DR   MINT; P18507; -.
DR   STRING; 9606.ENSP00000410732; -.
DR   BindingDB; P18507; -.
DR   ChEMBL; CHEMBL2094120; -.
DR   ChEMBL; CHEMBL2094121; -.
DR   ChEMBL; CHEMBL2094122; -.
DR   ChEMBL; CHEMBL2094130; -.
DR   ChEMBL; CHEMBL2095172; -.
DR   ChEMBL; CHEMBL2095190; -.
DR   ChEMBL; CHEMBL2111339; -.
DR   ChEMBL; CHEMBL2111366; -.
DR   ChEMBL; CHEMBL2111370; -.
DR   ChEMBL; CHEMBL2111392; -.
DR   ChEMBL; CHEMBL2111413; -.
DR   ChEMBL; CHEMBL4523638; -.
DR   ChEMBL; CHEMBL4523640; -.
DR   ChEMBL; CHEMBL4523641; -.
DR   DrugBank; DB12537; 1,2-Benzodiazepine.
DR   DrugBank; DB00546; Adinazolam.
DR   DrugBank; DB06579; Adipiplon.
DR   DrugBank; DB00404; Alprazolam.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB11901; Apalutamide.
DR   DrugBank; DB14719; Bentazepam.
DR   DrugBank; DB11859; Brexanolone.
DR   DrugBank; DB01558; Bromazepam.
DR   DrugBank; DB09017; Brotizolam.
DR   DrugBank; DB00237; Butabarbital.
DR   DrugBank; DB00241; Butalbital.
DR   DrugBank; DB01489; Camazepam.
DR   DrugBank; DB00395; Carisoprodol.
DR   DrugBank; DB00475; Chlordiazepoxide.
DR   DrugBank; DB14715; Cinazepam.
DR   DrugBank; DB01594; Cinolazepam.
DR   DrugBank; DB00349; Clobazam.
DR   DrugBank; DB01068; Clonazepam.
DR   DrugBank; DB00628; Clorazepic acid.
DR   DrugBank; DB01559; Clotiazepam.
DR   DrugBank; DB01553; Cloxazolam.
DR   DrugBank; DB01511; Delorazepam.
DR   DrugBank; DB01189; Desflurane.
DR   DrugBank; DB00829; Diazepam.
DR   DrugBank; DB13837; Doxefazepam.
DR   DrugBank; DB00228; Enflurane.
DR   DrugBank; DB01215; Estazolam.
DR   DrugBank; DB00402; Eszopiclone.
DR   DrugBank; DB00189; Ethchlorvynol.
DR   DrugBank; DB01545; Ethyl loflazepate.
DR   DrugBank; DB09166; Etizolam.
DR   DrugBank; DB00292; Etomidate.
DR   DrugBank; DB01567; Fludiazepam.
DR   DrugBank; DB01205; Flumazenil.
DR   DrugBank; DB01544; Flunitrazepam.
DR   DrugBank; DB00690; Flurazepam.
DR   DrugBank; DB05087; Ganaxolone.
DR   DrugBank; DB01381; Ginkgo biloba.
DR   DrugBank; DB01437; Glutethimide.
DR   DrugBank; DB00801; Halazepam.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB00753; Isoflurane.
DR   DrugBank; DB01587; Ketazolam.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB13643; Loprazolam.
DR   DrugBank; DB00186; Lorazepam.
DR   DrugBank; DB13872; Lormetazepam.
DR   DrugBank; DB13437; Medazepam.
DR   DrugBank; DB00603; Medroxyprogesterone acetate.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00371; Meprobamate.
DR   DrugBank; DB00463; Metharbital.
DR   DrugBank; DB01028; Methoxyflurane.
DR   DrugBank; DB01107; Methyprylon.
DR   DrugBank; DB15489; Mexazolam.
DR   DrugBank; DB00683; Midazolam.
DR   DrugBank; DB12458; Muscimol.
DR   DrugBank; DB01595; Nitrazepam.
DR   DrugBank; DB14028; Nordazepam.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00842; Oxazepam.
DR   DrugBank; DB14672; Oxazepam acetate.
DR   DrugBank; DB00312; Pentobarbital.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB13335; Pinazepam.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB01588; Prazepam.
DR   DrugBank; DB00794; Primidone.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB01589; Quazepam.
DR   DrugBank; DB12404; Remimazolam.
DR   DrugBank; DB01236; Sevoflurane.
DR   DrugBank; DB09118; Stiripentol.
DR   DrugBank; DB00306; Talbutal.
DR   DrugBank; DB01956; Taurine.
DR   DrugBank; DB00231; Temazepam.
DR   DrugBank; DB11582; Thiocolchicoside.
DR   DrugBank; DB00897; Triazolam.
DR   DrugBank; DB00425; Zolpidem.
DR   DrugBank; DB00909; Zonisamide.
DR   DrugCentral; P18507; -.
DR   TCDB; 1.A.9.5.4; the neurotransmitter receptor, cys loop, ligand-gated ion channel (lic) family.
DR   GlyCosmos; P18507; 3 sites, No reported glycans.
DR   GlyGen; P18507; 3 sites.
DR   iPTMnet; P18507; -.
DR   PhosphoSitePlus; P18507; -.
DR   SwissPalm; P18507; -.
DR   BioMuta; GABRG2; -.
DR   DMDM; 116242488; -.
DR   EPD; P18507; -.
DR   MassIVE; P18507; -.
DR   PeptideAtlas; P18507; -.
DR   ProteomicsDB; 27833; -.
DR   ProteomicsDB; 53569; -. [P18507-1]
DR   ProteomicsDB; 53570; -. [P18507-2]
DR   TopDownProteomics; P18507-2; -. [P18507-2]
DR   ABCD; P18507; 4 sequenced antibodies.
DR   Antibodypedia; 28585; 425 antibodies from 38 providers.
DR   DNASU; 2566; -.
DR   Ensembl; ENST00000414552.6; ENSP00000410732.2; ENSG00000113327.17. [P18507-3]
DR   Ensembl; ENST00000639111.2; ENSP00000492125.2; ENSG00000113327.17. [P18507-1]
DR   Ensembl; ENST00000639213.2; ENSP00000491909.2; ENSG00000113327.17. [P18507-2]
DR   GeneID; 2566; -.
DR   KEGG; hsa:2566; -.
DR   MANE-Select; ENST00000639213.2; ENSP00000491909.2; NM_198904.4; NP_944494.1. [P18507-2]
DR   UCSC; uc003lyy.5; human. [P18507-1]
DR   AGR; HGNC:4087; -.
DR   CTD; 2566; -.
DR   DisGeNET; 2566; -.
DR   GeneCards; GABRG2; -.
DR   HGNC; HGNC:4087; GABRG2.
DR   HPA; ENSG00000113327; Tissue enhanced (brain, retina).
DR   MalaCards; GABRG2; -.
DR   MIM; 137164; gene.
DR   MIM; 607681; phenotype.
DR   MIM; 618396; phenotype.
DR   neXtProt; NX_P18507; -.
DR   OpenTargets; ENSG00000113327; -.
DR   Orphanet; 64280; Childhood absence epilepsy.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 36387; Generalized epilepsy with febrile seizures-plus.
DR   Orphanet; 442835; Non-specific early-onset epileptic encephalopathy.
DR   Orphanet; 1945; Rolandic epilepsy.
DR   PharmGKB; PA28501; -.
DR   VEuPathDB; HostDB:ENSG00000113327; -.
DR   eggNOG; KOG3642; Eukaryota.
DR   GeneTree; ENSGT00940000156685; -.
DR   HOGENOM; CLU_010920_2_0_1; -.
DR   InParanoid; P18507; -.
DR   OMA; SAHYSLC; -.
DR   OrthoDB; 4265336at2759; -.
DR   PhylomeDB; P18507; -.
DR   TreeFam; TF315453; -.
DR   PathwayCommons; P18507; -.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-977443; GABA receptor activation.
DR   SignaLink; P18507; -.
DR   SIGNOR; P18507; -.
DR   BioGRID-ORCS; 2566; 14 hits in 1160 CRISPR screens.
DR   ChiTaRS; GABRG2; human.
DR   GeneWiki; GABRG2; -.
DR   GenomeRNAi; 2566; -.
DR   Pharos; P18507; Tclin.
DR   PRO; PR:P18507; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P18507; protein.
DR   Bgee; ENSG00000113327; Expressed in middle temporal gyrus and 137 other tissues.
DR   ExpressionAtlas; P18507; baseline and differential.
DR   Genevisible; P18507; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0032590; C:dendrite membrane; ISS:BHF-UCL.
DR   GO; GO:1902711; C:GABA-A receptor complex; IPI:ComplexPortal.
DR   GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0060077; C:inhibitory synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IBA:GO_Central.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0008503; F:benzodiazepine receptor activity; TAS:ProtInc.
DR   GO; GO:0005254; F:chloride channel activity; ISS:UniProtKB.
DR   GO; GO:0004890; F:GABA-A receptor activity; ISS:UniProtKB.
DR   GO; GO:0022851; F:GABA-gated chloride ion channel activity; IEA:Ensembl.
DR   GO; GO:0005237; F:inhibitory extracellular ligand-gated monoatomic ion channel activity; IBA:GO_Central.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IEA:Ensembl.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0071420; P:cellular response to histamine; ISS:UniProtKB.
DR   GO; GO:1902476; P:chloride transmembrane transport; IDA:ComplexPortal.
DR   GO; GO:0007214; P:gamma-aminobutyric acid signaling pathway; IDA:ComplexPortal.
DR   GO; GO:1904862; P:inhibitory synapse assembly; IDA:UniProtKB.
DR   GO; GO:0050877; P:nervous system process; IBA:GO_Central.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0060078; P:regulation of postsynaptic membrane potential; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0051932; P:synaptic transmission, GABAergic; ISS:BHF-UCL.
DR   CDD; cd19000; LGIC_ECD_GABAAR_G; 1.
DR   CDD; cd19054; LGIC_TM_GABAAR_gamma; 1.
DR   Gene3D; 2.70.170.10; Neurotransmitter-gated ion-channel ligand-binding domain; 1.
DR   Gene3D; 1.20.58.390; Neurotransmitter-gated ion-channel transmembrane domain; 1.
DR   InterPro; IPR006028; GABAA/Glycine_rcpt.
DR   InterPro; IPR005439; GABBAg2_rcpt.
DR   InterPro; IPR005437; GABRG-1/4.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR036734; Neur_chan_lig-bd_sf.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR036719; Neuro-gated_channel_TM_sf.
DR   InterPro; IPR038050; Neuro_actylchol_rec.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   PANTHER; PTHR18945:SF498; GAMMA-AMINOBUTYRIC ACID RECEPTOR SUBUNIT GAMMA-2; 1.
DR   PANTHER; PTHR18945; NEUROTRANSMITTER GATED ION CHANNEL; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 1.
DR   Pfam; PF02932; Neur_chan_memb; 1.
DR   PRINTS; PR00253; GABAARECEPTR.
DR   PRINTS; PR01620; GABAARGAMMA.
DR   PRINTS; PR01622; GABAARGAMMA2.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF90112; Neurotransmitter-gated ion-channel transmembrane pore; 1.
DR   SUPFAM; SSF63712; Nicotinic receptor ligand binding domain-like; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
DR   TIGRFAMs; TIGR00860; LIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cell projection;
KW   Chloride; Chloride channel; Cytoplasmic vesicle; Disease variant;
KW   Disulfide bond; Epilepsy; Glycoprotein; Ion channel; Ion transport;
KW   Lipoprotein; Membrane; Palmitate; Postsynaptic cell membrane;
KW   Reference proteome; Signal; Synapse; Transmembrane; Transmembrane helix;
KW   Transport.
FT   SIGNAL          1..39
FT                   /evidence="ECO:0000255"
FT   CHAIN           40..475
FT                   /note="Gamma-aminobutyric acid receptor subunit gamma-2"
FT                   /id="PRO_0000000477"
FT   TOPO_DOM        40..273
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        274..296
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        300..322
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        334..356
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   TOPO_DOM        357..451
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        452..474
FT                   /note="Helical"
FT                   /evidence="ECO:0000305"
FT   REGION          433..450
FT                   /note="Interaction with GABARAP"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        52
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        129
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        247
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        190..204
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         211
FT                   /note="Y -> WSRSIAQAGMCSGVISAHYSLRFWGSTDPPTLASRVAGISD (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_061922"
FT   VAR_SEQ         377..384
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_061923"
FT   VARIANT         79
FT                   /note="N -> S (found in a patient with generalized
FT                   tonic-clonic seizures; dbSNP:rs112894280)"
FT                   /evidence="ECO:0000269|PubMed:20485450"
FT                   /id="VAR_065226"
FT   VARIANT         82
FT                   /note="R -> Q (in ECA2 and FEB8; abolishes in vitro
FT                   sensitivity to diazepam; dbSNP:rs121909673)"
FT                   /evidence="ECO:0000269|PubMed:11326275"
FT                   /id="VAR_014265"
FT   VARIANT         83
FT                   /note="P -> S (found in a patient with idiopathic
FT                   generalized epilepsy; unknown pathological significance;
FT                   the currents elicited by mutant receptors are
FT                   indistinguishable from wild-type; no difference in
FT                   sensitivity of the mutant receptors to the allosteric
FT                   regulators zinc and benzodiazepine diazepam compared to
FT                   wild-type; dbSNP:rs587777365)"
FT                   /evidence="ECO:0000269|PubMed:21714819"
FT                   /id="VAR_071813"
FT   VARIANT         106
FT                   /note="A -> T (in DEE74; does not affect protein abundance;
FT                   decreases cell surface expression; decreases current
FT                   amplitude in response to GABA; does not affect zinc
FT                   sensitivity; accelerates activation and prolonges
FT                   deactivation; dbSNP:rs796052505)"
FT                   /evidence="ECO:0000269|PubMed:27864268"
FT                   /id="VAR_082266"
FT   VARIANT         107
FT                   /note="I -> T (in DEE74; increases protein abundance;
FT                   retained in the endoplasmic reticulum; decreases cell
FT                   surface expression; decreases current amplitude in response
FT                   to GABA; increases zinc sensitivity; accelerates activation
FT                   and prolonges deactivation)"
FT                   /evidence="ECO:0000269|PubMed:27864268"
FT                   /id="VAR_082267"
FT   VARIANT         177
FT                   /note="R -> G (in FEB8; dbSNP:rs267606837)"
FT                   /evidence="ECO:0000269|PubMed:16924025"
FT                   /id="VAR_038602"
FT   VARIANT         274
FT                   /note="Y -> C (probable disease-associated variant found in
FT                   a patient with generalized epilepsy with myoclonic atonic
FT                   seizures, cognitive impairment and behavioral disorder)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078226"
FT   VARIANT         282
FT                   /note="P -> S (in DEE74; increases protein abundance;
FT                   retained in the endoplasmic reticulum decreases; cell
FT                   surface expression; decreases current amplitude in response
FT                   to GABA; increases zinc sensitivity; accelerates activation
FT                   and prolonges deactivation; dbSNP:rs796052508)"
FT                   /evidence="ECO:0000269|PubMed:27864268"
FT                   /id="VAR_082268"
FT   VARIANT         323
FT                   /note="R -> Q (in GEFSP3 and DEE74; does not affect protein
FT                   abundance; decreases cell surface expression; decreases
FT                   current amplitude in response to GABA; increases zinc
FT                   sensitivity; accelerates deactivation; dbSNP:rs397514737)"
FT                   /evidence="ECO:0000269|PubMed:23708187,
FT                   ECO:0000269|PubMed:27864268"
FT                   /id="VAR_078620"
FT   VARIANT         323
FT                   /note="R -> W (in DEE74; does not affect protein abundance;
FT                   decreases cell surface expression; decreases current
FT                   amplitude in response to GABA; increases zinc sensitivity;
FT                   accelerates deactivation; dbSNP:rs796052510)"
FT                   /evidence="ECO:0000269|PubMed:27864268"
FT                   /id="VAR_082269"
FT   VARIANT         328
FT                   /note="K -> M (in GEFSP3; dbSNP:rs121909672)"
FT                   /evidence="ECO:0000269|PubMed:11326274"
FT                   /id="VAR_014266"
FT   VARIANT         343
FT                   /note="F -> L (in DEE74; does not affect protein abundance;
FT                   decreases cell surface expression; decreases current
FT                   amplitude in response to GABA; does not affect zinc
FT                   sensitivity; accelerates activation and prolonges
FT                   deactivation; dbSNP:rs796052511 and dbSNP:rs1554100923)"
FT                   /evidence="ECO:0000269|PubMed:27864268"
FT                   /id="VAR_082270"
FT   VARIANT         357
FT                   /note="H -> R (in dbSNP:rs17855003)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_065163"
FT   CONFLICT        120
FT                   /note="T -> M (in Ref. 1; CAA33437)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        181
FT                   /note="T -> S (in Ref. 1; CAA33437)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        392..393
FT                   /note="Missing (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        407
FT                   /note="E -> D (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        446..447
FT                   /note="IA -> RI (in Ref. 5; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   HELIX           65..73
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            74..76
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            83..87
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          90..105
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            106..109
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          110..122
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           124..126
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          130..132
FT                   /evidence="ECO:0007829|PDB:6I53"
FT   STRAND          134..137
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           139..144
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          155..160
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          163..165
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          168..173
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          176..189
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            195..198
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          201..212
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   TURN            215..217
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          218..229
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          232..235
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          238..254
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          257..270
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           274..291
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           292..295
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           301..323
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   STRAND          324..326
FT                   /evidence="ECO:0007829|PDB:6HUJ"
FT   HELIX           334..359
FT                   /evidence="ECO:0007829|PDB:6X3T"
FT   HELIX           448..473
FT                   /evidence="ECO:0007829|PDB:6X3T"
SQ   SEQUENCE   475 AA;  55186 MW;  DE142F62846576DF CRC64;
     MSSPNIWSTG SSVYSTPVFS QKMTVWILLL LSLYPGFTSQ KSDDDYEDYA SNKTWVLTPK
     VPEGDVTVIL NNLLEGYDNK LRPDIGVKPT LIHTDMYVNS IGPVNAINME YTIDIFFAQT
     WYDRRLKFNS TIKVLRLNSN MVGKIWIPDT FFRNSKKADA HWITTPNRML RIWNDGRVLY
     TLRLTIDAEC QLQLHNFPMD EHSCPLEFSS YGYPREEIVY QWKRSSVEVG DTRSWRLYQF
     SFVGLRNTTE VVKTTSGDYV VMSVYFDLSR RMGYFTIQTY IPCTLIVVLS WVSFWINKDA
     VPARTSLGIT TVLTMTTLST IARKSLPKVS YVTAMDLFVS VCFIFVFSAL VEYGTLHYFV
     SNRKPSKDKD KKKKNPLLRM FSFKAPTIDI RPRSATIQMN NATHLQERDE EYGYECLDGK
     DCASFFCCFE DCRTGAWRHG RIHIRIAKMD SYARIFFPTA FCLFNLVYWV SYLYL
//
